6 月 20 日,NMPA 官网显示,先声药业与瑞士 Idorsia 公司合作开发的抗失眠创新药科唯可®(盐酸达利雷生片)获批上市(受理号:JXHS2400049/50)。*如需获取 2025 年更多新药获批情报,扫描文末二维码添加小音,即可免费下载。截图来自:NMPA 官网达利雷生是一种双食欲素受体拮抗剂,属于新一代抗失眠药,已在美国、英国、瑞士、加拿大、日本等多个国家和地区获批上市。与传统镇静...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.